Michael G. Moore
Voorzitter bij Macrophage Pharma Ltd.
Oorsprong van het eerstegraads netwerk van Michael G. Moore
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Biotechnology | 18 | |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.
15
| Holding Company | Pharmaceuticals: Major | 15 |
Mironid Ltd.
 Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.
8
| Subsidiary | Miscellaneous Commercial Services | 8 |
Macrophage Pharma Ltd.
 Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.
6
| Holding Company | Biotechnology | 6 |
Chronos Therapeutics Ltd.
 Chronos Therapeutics Ltd. BiotechnologyHealth Technology Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom.
5
| Private Company | Biotechnology | 5 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.
4
| Extinct | Miscellaneous Commercial Services | 4 |
Xenova Group Plc
 Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK
3
| Extinct | Miscellaneous Commercial Services | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Michael G. Moore via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor Corporate Officer/Principal Director/Board Member | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member | |
| VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| SEAGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| ONCOSEC MEDICAL INCORPORATED | Medical/Nursing Services | Director/Board Member Chief Operating Officer | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Pennsylvania | College/University | Doctorate Degree Doctorate Degree | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| University of Glasgow | College/University | Graduate Degree Doctorate Degree | |
| University of Cambridge | College/University | Graduate Degree Doctorate Degree | |
| University of Leeds | College/University | Doctorate Degree Undergraduate Degree | |
| University of London | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Toronto | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of California San Diego | College/University | Undergraduate Degree Graduate Degree | |
| University of Bristol | College/University | Undergraduate Degree Doctorate Degree | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Founder Corporate Officer/Principal Corporate Officer/Principal | |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Chief Executive Officer Director/Board Member | |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
| The University of Nottingham | College/University | Undergraduate Degree Doctorate Degree | |
| University College London | College/University | Corporate Officer/Principal Undergraduate Degree | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder Chief Operating Officer | |
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member Director/Board Member | |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| MERUS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
| OSI Pharmaceuticals (UK) Ltd. | Director/Board Member Corporate Officer/Principal | ||
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Epidarex Capital Partners LLC
 Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Investment Managers | Founder Private Equity Investor | |
| ALLAKOS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ixaka Ltd.
 Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
General Inception
 General Inception Investment ManagersFinance General Inception Management LLC (General Inception Management) is a venture capital firm founded in 2020 by Vikram Chaudhery, Paul A. Conley and Jim Buzzitta. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
Bristol-Myers Squibb FCT bêta, Inc.
 Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Verenigd Koninkrijk | 25 |
| Verenigde Staten | 15 |
| Canada | 5 |
| Denemarken | 3 |
| Nederland | 3 |
Sectoraal
| Health Technology | 31 |
| Consumer Services | 12 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 377 |
| Corporate Officer/Principal | 153 |
| Independent Dir/Board Member | 52 |
| Chairman | 50 |
| Founder | 43 |
Sterkste connecties
| Insiders | |
|---|---|
| Calvin Stiller | 38 |
| Elaine Jones | 37 |
| Deborah Harland | 27 |
| Graziano Seghezzi | 26 |
| Colin Goddard | 26 |
| Carole Nüchterlein | 26 |
| Maina Bhaman | 26 |
| Anker Gunvald Lundemose | 25 |
| Bobby G. Soni | 23 |
| Michael Berendt | 20 |
| Jonathan Hepple | 19 |
| Luke Beshar | 19 |
| Andrew Dunlop | 18 |
| Hakan Goker | 18 |
| Elizabeth Ann Roper | 16 |
- Beurs
- Insiders
- Michael G. Moore
- Bedrijfsconnecties
